Selected article for: "bacterial infection and high mxa"
Author: Lagi, Filippo; Trevisan, Sasha; Piccica, Matteo; Graziani, Lucia; Basile, Gregorio; Mencarini, Jessica; Borchi, Beatrice; Menicacci, Lorenzo; Vaudo, Micol; Scotti, Valentina; Fabbri, Alessia; Bandini, Giulia; Tozzetti, Camilla; Berni, Andrea; Aiezza, Noemi; Pestelli, Giulia; Turchi, Valerio; Pignone, Alberto Moggi; Poggesi, Loredana; Nozzoli, Carlo; Morettini, Alessandro; Rossolini, Gian Maria; Bartoloni, Alessandro
Title: Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy
  • Cord-id: d51ewk67
  • Document date: 2021_4_24
    • ID: d51ewk67
    Snippet: OBJECTIVE: Evaluate the real-world accuracy of Myxovirus resistance protein A (MxA) detected by the rapid, point-of-care FebriDx test during the second-wave pandemic in Italy in patients with acute respiratory infection (ARI) and a clinical suspicion of COVID-19. DESIGN AND METHODS: Prospective, observational, diagnostic accuracy study whereby hospitalized patients with ARI were consecutively enrolled in a single tertiary care center in Italy from August 1, 2020 to January 31, 2021. RESULTS: COV
    Document: OBJECTIVE: Evaluate the real-world accuracy of Myxovirus resistance protein A (MxA) detected by the rapid, point-of-care FebriDx test during the second-wave pandemic in Italy in patients with acute respiratory infection (ARI) and a clinical suspicion of COVID-19. DESIGN AND METHODS: Prospective, observational, diagnostic accuracy study whereby hospitalized patients with ARI were consecutively enrolled in a single tertiary care center in Italy from August 1, 2020 to January 31, 2021. RESULTS: COVID-19 was diagnosed in 136/200 (68.0%) patients and Non-COVID-19 was diagnosed in64/200 (32.0%) patients. COVID-19 patients were younger and had a lower Charlson comorbidity index compared to non-COVID-19 patients (p < 0.001). Concordance between FebriDx, MxA and rt-PCR for SARS-CoV-2 (gold standard) was good (k 0.93, 95%CI 0.87-0.99). Overall sensitivity and specificity were 97.8% [95%CI 93.7-99.5] and 95.3% [95%CI 86.9%-99.0%], respectively. FebriDx demonstrated a negative predictive value of 95.3% (95%CI 86.9-99.0) for an observed disease prevalence of 68%. CONCLUSIONS: FebriDx MxA showed high diagnostic accuracy to identify COVID-19 and could be considered as a real-time triage tool to streamline the management of suspected COVID-19 patients. FebriDx also detected bacterial etiology in non-COVID-19 patients suggesting good performance to distinguish bacterial from viral respiratory infection.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute phase: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and acute phase protein: 1
    • absence presence and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and acute respiratory viral etiology: 1
    • absence presence and admission prior: 1
    • absence presence and low disease: 1, 2, 3, 4, 5, 6, 7
    • absence presence and low prevalence: 1, 2, 3, 4
    • acid amplification technology and acute respiratory: 1, 2, 3, 4
    • acid amplification technology and acute respiratory syndrome: 1, 2, 3
    • acid amplification technology and low prevalence: 1
    • active pathology and acute respiratory: 1
    • active pathology and acute respiratory syndrome: 1
    • acute ari respiratory infection and low prevalence: 1
    • acute inflammation and admission prior: 1, 2
    • acute inflammation and low disease: 1, 2
    • acute phase and low disease: 1, 2, 3, 4, 5
    • acute phase and low disease prevalence: 1
    • acute phase and low prevalence: 1, 2, 3, 4, 5, 6, 7